Table 3. Alternation of treatment with ADA (patients diagnosed with spondyloarthropathy-associated uveitis were excluded) .

-	Prior to ADA	Concomitant with ADA	p value
The number of agents, mean, median (IQR)	1.4 1 (1-2)	1.1 1 (1-1)	<0.001
Immunosuppressive drug load, mean, median (IQR)	6.7 6.5 (4-10)	5.6 5 (4-7)	0.002
The number of local treatments, mean, median (IQR)	1.1 0 (0-1)	0.3 0 (0-0)	<0.001

Wilcoxon signed-rank test. IQR: Interquartile range, ADA: Adalimumab. Significant p values written in bold